The Latin America, Middle East and Africa Gastrointestinal Therapeutics Market should witness market growth of 9.6% CAGR during the forecast period (2022-2028).
Structural gastrointestinal disease is when one’s bowel looks abnormal during the examination and doesn’t function properly. In some cases, the structural abnormality is required to be removed surgically. Structural GI diseases include strictures, hemorrhoids, inflammatory bowel disease, colon cancer, colon polyps, and stenosis.
Constipation, a functional problem, makes it hard for the patient to have a bowel movement (or pass stools). As a result, the stools are infrequent (less than three times a week) or incomplete. Constipation is generally caused by an inadequate “roughage” or fiber in one’s diet or disruption in their routine. Constipation usually doesn’t mean any serious medical condition.
Irritable bowel syndrome (also called spastic colon, IBS, nervous stomach or irritable colon) is a functional condition where the patients colon muscle contracts more or less often than “normal”. Certain foods, medicines and emotional stress are some factors which are known to triggers IBS. Hemorrhoids are expanded veins in the anal canal, which cause a structural disease.
Dubai spent around AED 19.49 billion on healthcare which was 5.3 % of their GDP, the annual growth rate was just 1% after accounting for change in the utilization pattern because of the COVID-19 pandemic. The spending on ancillary services and medical goods was 13% and 15% respectively. The spending on perspective care services were lower than 1% and the government allocated 23% of their health expenditure to administration and governance functions. The private insurance spent 36% of their total health expenditure on ancillary services and medical goods.
The Brazil market dominated the LAMEA Gastrointestinal Therapeutics Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $1, 032.1 million by 2028. The Argentina market is estimated to grow a CAGR of 10.2% during (2022-2028). Additionally, The UAE market would experience a CAGR of 9.3% during (2022-2028).
Based on Type, the market is segmented into Branded and Generics. Based on Distribution Channel, the market is segmented into Retail Pharmacies, Hospital Pharmacies and Online Pharmacies. Based on Route of Administration, the market is segmented into Injectable and Oral & Others. Based on Application, the market is segmented into Crohn's Disease, Ulcerative Colitis, GERD, IBS and Others. Based on Drug Class, the market is segmented into Biologics/Biosimilar, Anti-Diarrheal, Anti-Emetics, Digestive Enzymes, Aminosalicylates, Proton Pump Inhibitors, Laxatives & H2 Antagonists and Others. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Abbott Laboratories, AbbVie, Inc., Takeda Pharmaceutical Company Limited, Pfizer, Inc., Salix Pharmaceuticals, Inc. (Bausch Health Companies, Inc.), Johnson & Johnson (Janssen Global Services, LLC), AstraZeneca PLC, Bayer AG, Sun Pharmaceutical Industries Ltd., and Cipla Limited.
Structural gastrointestinal disease is when one’s bowel looks abnormal during the examination and doesn’t function properly. In some cases, the structural abnormality is required to be removed surgically. Structural GI diseases include strictures, hemorrhoids, inflammatory bowel disease, colon cancer, colon polyps, and stenosis.
Constipation, a functional problem, makes it hard for the patient to have a bowel movement (or pass stools). As a result, the stools are infrequent (less than three times a week) or incomplete. Constipation is generally caused by an inadequate “roughage” or fiber in one’s diet or disruption in their routine. Constipation usually doesn’t mean any serious medical condition.
Irritable bowel syndrome (also called spastic colon, IBS, nervous stomach or irritable colon) is a functional condition where the patients colon muscle contracts more or less often than “normal”. Certain foods, medicines and emotional stress are some factors which are known to triggers IBS. Hemorrhoids are expanded veins in the anal canal, which cause a structural disease.
Dubai spent around AED 19.49 billion on healthcare which was 5.3 % of their GDP, the annual growth rate was just 1% after accounting for change in the utilization pattern because of the COVID-19 pandemic. The spending on ancillary services and medical goods was 13% and 15% respectively. The spending on perspective care services were lower than 1% and the government allocated 23% of their health expenditure to administration and governance functions. The private insurance spent 36% of their total health expenditure on ancillary services and medical goods.
The Brazil market dominated the LAMEA Gastrointestinal Therapeutics Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $1, 032.1 million by 2028. The Argentina market is estimated to grow a CAGR of 10.2% during (2022-2028). Additionally, The UAE market would experience a CAGR of 9.3% during (2022-2028).
Based on Type, the market is segmented into Branded and Generics. Based on Distribution Channel, the market is segmented into Retail Pharmacies, Hospital Pharmacies and Online Pharmacies. Based on Route of Administration, the market is segmented into Injectable and Oral & Others. Based on Application, the market is segmented into Crohn's Disease, Ulcerative Colitis, GERD, IBS and Others. Based on Drug Class, the market is segmented into Biologics/Biosimilar, Anti-Diarrheal, Anti-Emetics, Digestive Enzymes, Aminosalicylates, Proton Pump Inhibitors, Laxatives & H2 Antagonists and Others. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Abbott Laboratories, AbbVie, Inc., Takeda Pharmaceutical Company Limited, Pfizer, Inc., Salix Pharmaceuticals, Inc. (Bausch Health Companies, Inc.), Johnson & Johnson (Janssen Global Services, LLC), AstraZeneca PLC, Bayer AG, Sun Pharmaceutical Industries Ltd., and Cipla Limited.
Scope of the Study
By Type
- Branded
- Generics
By Distribution Channel
- Retail Pharmacies
- Hospital Pharmacies
- Online Pharmacies
By Route of Administration
- Injectable
- Oral & Others
By Application
- Crohn's Disease
- Ulcerative Colitis
- GERD
- IBS
- Others
By Drug Class
- Biologics/Biosimilar
- Anti-Diarrheal
- Anti-Emetics
- Digestive Enzymes
- Aminosalicylates
- Proton Pump Inhibitors
- Laxatives & H2 Antagonists
- Others
By Country
- Brazil
- Argentina
- UAE
- Saudi Arabia
- South Africa
- Nigeria
- Rest of LAMEA
Key Market Players
List of Companies Profiled in the Report:
- Abbott Laboratories
- AbbVie, Inc.
- Takeda Pharmaceutical Company Limited
- Pfizer, Inc.
- Salix Pharmaceuticals, Inc. (Bausch Health Companies, Inc.)
- Johnson & Johnson (Janssen Global Services, LLC)
- AstraZeneca PLC
- Bayer AG
- Sun Pharmaceutical Industries Ltd.
- Cipla Limited
Unique Offerings
- Exhaustive coverage
- The highest number of market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 LAMEA Gastrointestinal Therapeutics Market, by Type
1.4.2 LAMEA Gastrointestinal Therapeutics Market, by Distribution Channel
1.4.3 LAMEA Gastrointestinal Therapeutics Market, by Route of Administration
1.4.4 LAMEA Gastrointestinal Therapeutics Market, by Application
1.4.5 LAMEA Gastrointestinal Therapeutics Market, by Drug Class
1.4.6 LAMEA Gastrointestinal Therapeutics Market, by Country
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market Composition & Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. Strategies Deployed in Gastrointestinal Therapeutics Market
Chapter 4. LAMEA Gastrointestinal Therapeutics Market by Type
4.1 LAMEA Branded Market by Country
4.2 LAMEA Generics Market by Country
Chapter 5. LAMEA Gastrointestinal Therapeutics Market by Distribution Channel
5.1 LAMEA Retail Pharmacies Market by Country
5.2 LAMEA Hospital Pharmacies Market by Country
5.3 LAMEA Online Pharmacies Market by Country
Chapter 6. LAMEA Gastrointestinal Therapeutics Market by Route of Administration
6.1 LAMEA Injectable Market by Country
6.2 LAMEA Oral & Others Market by Country
Chapter 7. LAMEA Gastrointestinal Therapeutics Market by Application
7.1 LAMEA Crohn's Disease Market by Country
7.2 LAMEA Ulcerative Colitis Market by Country
7.3 LAMEA GERD Market by Country
7.4 LAMEA IBS Market by Country
7.5 LAMEA Others Market by Country
Chapter 8. LAMEA Gastrointestinal Therapeutics Market by Drug Class
8.1 LAMEA Biologics/Biosimilar Market by Country
8.2 LAMEA Anti-Diarrheal Market by Country
8.3 LAMEA Anti-Emetics Market by Country
8.4 LAMEA Digestive Enzymes Market by Country
8.5 LAMEA Aminosalicylates Market by Country
8.6 LAMEA Proton Pump Inhibitors Market by Country
8.7 LAMEA Laxatives & H2 Antagonists Market by Country
8.8 LAMEA Others Market by Country
Chapter 9. LAMEA Gastrointestinal Therapeutics Market by Country
9.1 Brazil Gastrointestinal Therapeutics Market
9.1.1 Brazil Gastrointestinal Therapeutics Market by Type
9.1.2 Brazil Gastrointestinal Therapeutics Market by Distribution Channel
9.1.3 Brazil Gastrointestinal Therapeutics Market by Route of Administration
9.1.4 Brazil Gastrointestinal Therapeutics Market by Application
9.1.5 Brazil Gastrointestinal Therapeutics Market by Drug Class
9.2 Argentina Gastrointestinal Therapeutics Market
9.2.1 Argentina Gastrointestinal Therapeutics Market by Type
9.2.2 Argentina Gastrointestinal Therapeutics Market by Distribution Channel
9.2.3 Argentina Gastrointestinal Therapeutics Market by Route of Administration
9.2.4 Argentina Gastrointestinal Therapeutics Market by Application
9.2.5 Argentina Gastrointestinal Therapeutics Market by Drug Class
9.3 UAE Gastrointestinal Therapeutics Market
9.3.1 UAE Gastrointestinal Therapeutics Market by Type
9.3.2 UAE Gastrointestinal Therapeutics Market by Distribution Channel
9.3.3 UAE Gastrointestinal Therapeutics Market by Route of Administration
9.3.4 UAE Gastrointestinal Therapeutics Market by Application
9.3.5 UAE Gastrointestinal Therapeutics Market by Drug Class
9.4 Saudi Arabia Gastrointestinal Therapeutics Market
9.4.1 Saudi Arabia Gastrointestinal Therapeutics Market by Type
9.4.2 Saudi Arabia Gastrointestinal Therapeutics Market by Distribution Channel
9.4.3 Saudi Arabia Gastrointestinal Therapeutics Market by Route of Administration
9.4.4 Saudi Arabia Gastrointestinal Therapeutics Market by Application
9.4.5 Saudi Arabia Gastrointestinal Therapeutics Market by Drug Class
9.5 South Africa Gastrointestinal Therapeutics Market
9.5.1 South Africa Gastrointestinal Therapeutics Market by Type
9.5.2 South Africa Gastrointestinal Therapeutics Market by Distribution Channel
9.5.3 South Africa Gastrointestinal Therapeutics Market by Route of Administration
9.5.4 South Africa Gastrointestinal Therapeutics Market by Application
9.5.5 South Africa Gastrointestinal Therapeutics Market by Drug Class
9.6 Nigeria Gastrointestinal Therapeutics Market
9.6.1 Nigeria Gastrointestinal Therapeutics Market by Type
9.6.2 Nigeria Gastrointestinal Therapeutics Market by Distribution Channel
9.6.3 Nigeria Gastrointestinal Therapeutics Market by Route of Administration
9.6.4 Nigeria Gastrointestinal Therapeutics Market by Application
9.6.5 Nigeria Gastrointestinal Therapeutics Market by Drug Class
9.7 Rest of LAMEA Gastrointestinal Therapeutics Market
9.7.1 Rest of LAMEA Gastrointestinal Therapeutics Market by Type
9.7.2 Rest of LAMEA Gastrointestinal Therapeutics Market by Distribution Channel
9.7.3 Rest of LAMEA Gastrointestinal Therapeutics Market by Route of Administration
9.7.4 Rest of LAMEA Gastrointestinal Therapeutics Market by Application
9.7.5 Rest of LAMEA Gastrointestinal Therapeutics Market by Drug Class
Chapter 10. Company Profiles
10.1 Abbott Laboratories
10.1.1 Company Overview
10.1.2 Financial Analysis
10.1.3 Segmental and Regional Analysis
10.1.4 Research & Development Expense
10.1.5 SWOT Analysis
10.2 AbbVie, Inc.
10.2.1 Company Overview
10.2.2 Financial Analysis
10.2.3 Regional Analysis
10.2.4 Research & Development Expense
10.2.5 Recent strategies and developments:
10.2.5.1 Approvals and Trials:
10.3 Takeda Pharmaceutical Company Limited
10.3.1 Company Overview
10.3.2 Financial Analysis
10.3.3 Regional Analysis
10.3.4 Research & Development Expense
10.3.5 Recent strategies and developments:
10.3.5.1 Partnerships, Collaborations, and Agreements:
10.3.5.2 Acquisition and Mergers:
10.4 Pfizer, Inc.
10.4.1 Company Overview
10.4.2 Financial Analysis
10.4.3 Regional & Segmental Analysis
10.4.4 Research & Development Expense
10.4.5 Recent strategies and developments:
10.4.5.1 Partnerships, Collaborations, and Agreements:
10.5 Salix Pharmaceuticals, Inc. (Bausch Health Companies, Inc.)
10.5.1 Company Overview
10.5.2 Financial Analysis
10.5.3 Segmental and Regional Analysis
10.5.4 Research & Development Expense
10.5.5 Recent strategies and developments:
10.5.5.1 Product Launches and Product Expansions:
10.6 Johnson & Johnson (Janssen Global Services, LLC)
10.6.1 Company Overview
10.6.2 Financial Analysis
10.6.3 Segmental &Regional Analysis
10.6.4 Research & Development Expenses
10.6.5 Recent strategies and developments:
10.6.5.1 Partnerships, Collaborations, and Agreements:
10.7 AstraZeneca PLC
10.7.1 Company Overview
10.7.2 Financial Analysis
10.7.3 Regional Analysis
10.7.4 Research & Development Expenses
10.8 Bayer AG
10.8.1 Company Overview
10.8.2 Financial Analysis
10.8.3 Segmental and Regional Analysis
10.8.4 Research & Development Expense
10.9 Sun Pharmaceutical Industries Ltd.
10.9.1 Company Overview
10.9.2 Financial Analysis
10.9.3 Research & Development Expenses
10.10. Cipla Limited
10.10.1 Company Overview
10.10.2 Financial Analysis
10.10.3 Regional Analysis
10.10.4 Research & Development Expense
Companies Mentioned
- Abbott Laboratories
- AbbVie, Inc.
- Takeda Pharmaceutical Company Limited
- Pfizer, Inc.
- Salix Pharmaceuticals, Inc. (Bausch Health Companies, Inc.)
- Johnson & Johnson (Janssen Global Services, LLC)
- AstraZeneca PLC
- Bayer AG
- Sun Pharmaceutical Industries Ltd.
- Cipla Limited
Methodology
LOADING...
